Sales & Support: +44 (0)1223 316 855

Glioma research antibody citations

Haberler, C. and Wöhrer, A. (2014). Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas. Clinical Neuropathology, [online] 33(2), pp.108–111. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967248/ [Accessed 24 Jan. 2022].

Lee, Y., Koh, J., Kim, S.-I., Won, J.K., Park, C.-K., Choi, S.H. and Park, S.-H. (2017). The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas. Acta Neuropathologica Communications, [online] 5. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574236/ [Accessed 5 Mar. 2021].

Li, X., Wei, J., Liu, Y., Li, P., Fan, L., Wang, Y., Li, M., Zhao, D., Yu, Z., Ye, J., Guo, Y., Yan, Q., Guo, S. and Wang, Z. (2017). Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss. Scientific Reports, [online] 7(1), p.13038. Available at: https://www.nature.com/articles/s41598-017-13272-9 [Accessed 24 Jan. 2022].

Murnyák, B., Kouhsari, M.C., Hershkovitch, R., Kálmán, B., Marko-Varga, G., Klekner, Á. and Hortobágyi, T. (2017). PARP1expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma. Oncotarget, 8(28), pp.46348–46362.

Oktay, Y., Ülgen, E., Can, Ö., Akyerli, C.B., Yüksel, Ş., Erdemgil, Y., Durası, I.M., Henegariu, O.I., Nanni, E.P., Selevsek, N., Grossmann, J., Erson-Omay, E.Z., Bai, H., Gupta, M., Lee, W., Turcan, Ş., Özpınar, A., Huse, J.T., Sav, M.A. and Flanagan, A. (2016). IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation. Scientific Reports, [online] 6, p.27569. Available at: https://pubmed.ncbi.nlm.nih.gov/27282637/ [Accessed 24 Jan. 2022].

Rosager, A.M., Sørensen, M.D., Dahlrot, R.H., Boldt, H.B., Hansen, S., Lathia, J.D. and Kristensen, B.W. (2017). Expression and prognostic value of JAM-A in gliomas. Journal of Neuro-Oncology, [online] 135(1), pp.107–117. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658466/ [Accessed 24 Jan. 2022].

Valentini, M.C., Mellai, M., Annovazzi, L., Melcarne, A., Denysenko, T., Cassoni, P., Casalone, C., Maurella, C., Grifoni, S., Fania, P., Cistaro, A. and Schiffer, D. (2017). Comparison among conventional and advanced MRI, 18F-FDG PET/CT, phenotype and genotype in glioblastoma. Oncotarget, 8(53).